EP1841754A1

EP1841754A1 - N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application

Info

Publication number: EP1841754A1
Application number: EP06709122A
Authority: EP
Inventors: Francis Barth; Christian Congy; Jean-Philippe Ducoux; Murielle Rinaldi-Carmona
Original assignee: Sanofi Aventis France
Current assignee: Sanofi SA
Priority date: 2005-01-19
Filing date: 2006-01-18
Publication date: 2007-10-10
Also published as: TW200637838A; FR2880890B1; JP2008527026A; CN101119985A; WO2006077320A1; AU2006207382A1; RU2007131275A; KR20070107048A; AR053116A1; US20070287744A1; UY29338A1; CA2595045A1; FR2880890A1; IL184487A0; MX2007008792A; US7589120B2; BRPI0606450A2

Abstract

The invention relates to compounds of formula (I) in which: X represents an -SO- or -SO2- group; R1 representing: a (C1-C7) alkyl; a (C3-C12) non-aromatic carbocyclic radical; a (C3-C7) cycloalkylmethyl; an unsubstituted, mono-, di- or trisubstituted phenyl; a unsubstituted, mono-, di- or trisubstituted benzyl on the phenyl; a unsubstituted, mono-, di- or trisubstituted phenethyl on the phenyl; an unsubstituted, mono-, di- or trisubstituted naphtyl; a benzhydryl; a benzhydryl methyl, and; an aromatic heterocyclic radical, R2 represents a hydrogen atom or a (C1-C3) alkyl group; R3 represents an unsubstituted, mono-, di- or trisubstituted phenyl; R4 represents an unsubstituted, mono-, di- or trisubstituted phenyl; n represents 0, 1 or 2, and; Alk represents a (C1-C4) alkyl. The invention also relates to a method for preparing the aforementioned compounds and to their therapeutic application.

Description

N - [(4,5-DTHHENYL-2-THFINYL) METHYL] SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.

The present invention relates to substituted N - [(4,5-diphenyl-2-thienyl) methyl] sulfonamide derivatives, their preparation and their therapeutic application.

Diphenylpyrazole derivatives having an affinity for the CB 1 receptors of cannabinoids have been described in particular in patents US 5,624,941, EP 0 576 357, EP 0 656 354, EP 1 150 961 and WO 2005/073197.

4,5-Diarylthiophene derivatives _. having anti-inflammatory and analgesic properties are described in international applications WO 91/19708 and in patent applications EPO 024 042, EP 0 055 470, EPO 055 471 and US 4,432,974.

Thiophene-2-carboxamide derivatives are described in international application WO 2005/035488.

Novel substituted N- [(4,5-diphenyl-2-thienyl) methyl] sulfonamide derivatives have now been found which possess CB1 receptor antagonist properties of cannabinoids.

The subject of the present invention is compounds corresponding to formula (I):

in which :

X represents a group -SO- or -SO 2 -; • R _] [represents:

. a (C ₁ -C ₇ ) alkyl;

. a non-aromatic (C 3 -C 12) carbocyclic radical which is unsubstituted or substituted one or more times with a (C 1 -C 4) alkyl; . a (C 3 -C 7) cycloalkylmethyl which is unsubstituted or substituted one or more times on the carbocycle by a (C 1 -C 4) alkyl;

. unsubstituted or mono-, di- or tri-substituted phenyl with substituents independently selected from halogen, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy, (C 1 -C 4) alkylamino, di (C 1 -C 4) alkylamino, a cyano, a trifluoromethyl radical, a trifluoromethoxy radical, a S (O) _n AIk group, a (C 1 -C 4) alkylcarbonyl group; or from a phenyl, phenoxy, pyrrolyl, imidazolyl, pyridyl or pyrazolyl radical, said radicals being unsubstituted or substituted one or more times by a (C 1 -C 4) alkyl; . benzyl which is unsubstituted or mono- or disubstituted on the phenyl by substituents independently selected from halogen, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy, trifluoromethyl or alpha-substituted with one or two similar or different groups selected from (C 1 -C 4) alkyl, (C 3 -C 7) cycloalkyl;

. phenethyl which is unsubstituted or mono- or disubstituted on phenyl by substituents independently selected from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy, a trifluoromethyl radical; . unsubstituted or mono- or disubstituted naphthyl with substituents independently selected from (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy, trifluoromethyl;

. a benzhydryl; benzhydrylmethyl;

. an aromatic heterocyclic radical chosen from pyrrolyl, imidazolyl, furyl, thienyl, pyrazolyl, indolyl, 2,3-dihydrobenzofuryl which is unsubstituted or substituted one or more times with substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a trifluoromethyl radical;

R 2 represents a hydrogen atom or a (C 1 -C 3) alkyl group;

R 3 represents an unsubstituted or mono-, di- or trisubstituted phenyl with substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy, a trifluoromethyl radical or a group S (O) _n AIk;

R 4 represents an unsubstituted or mono-, di- or trisubstituted phenyl by substituents independently selected from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy, a trifluoromethyl radical or a group S (O) _n AIk;

n represents 0, 1 or 2;

Alk represents a (C 1 -C 4) alkyl.

The compounds of formula (I) may comprise one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers and mixtures thereof, including racemic mixtures, form part of the invention.

The compounds of formula (I) may exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates are also part of the invention.

By halogen atom is meant a bromine, chlorine, fluorine or iodine atom.

By (C 1 -C 3) alkyl or (C 1 -C 4) alkyl or (C 1 -C 7) alkyl, it is meant a linear or branched alkyl radical of one to three carbon atoms or of one to four carbon atoms or of one to four carbon atoms respectively. to seven carbon atoms, such as, for example, the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl and heptyl radicals.

(C1-C4) alkoxy means a linear or branched alkoxy radical of one to four carbon atoms, such as the methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy or tert-butoxy radical.

By (C3-C7) cycloalkyl is meant a cyclic alkyl group of 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl.

C3-C12 non-aromatic carbocyclic radicals include mono or polycyclic radicals, fused, bridged or spiranic. Monocyclic radicals include cycloalkyls for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl. The fused, bridged or spiro di- or tricyclic radicals include, for example, norbornyl, bornyl, isobornyl, noradamantyl, adamantyl, spiro [5.5] undecyl, bicyclo [2.2.1] heptyl, bicyclo [3.2.1] octyl; bicyclo [3.1.1] heptyl.

Among the compounds of formula (I), objects of the invention, there are:

the compounds of formula (IA) in which -X- represents a radical -SO- and the substituents R4 to R4 are as defined for the compounds of formula (I);

the compounds of formula (IB) in which -X- represents a radical -SO2- and the substituents R1 to R4 are as defined for the compounds of formula (I).

According to the present invention, the compounds of formula (I) in which:

X represents a group -SO 2 -,

- Rj represents:

. a (C1-C7) alkyl unsubstituted or substituted one or more times with a halogen atom; . a (C 3 -C 7) cycloalkyl which is unsubstituted or substituted one or more times with a (C 1 -C 3) alkyl group; . a (C 3 -C 7) cycloalkylmethyl which is unsubstituted or substituted one or more times on the carbocycle by a (C 1 -C 3) alkyl; . unsubstituted or mono-, di- or tri-substituted phenyl with substituents independently selected from halogen, (C1-C4) alkyl, (C1-C4) alkoxy, cyano, trifluoromethyl, radical trifluoromethoxy, S (O) _n Alk, (C 1 -C 4) alkylcarbonyl, phenyl;

. benzyl which is unsubstituted or mono- or disubstituted with substituents independently selected from halogen, (C1-C4) alkyl, (C1-C4) alkoxy, trifluoromethyl;

R 2 represents a hydrogen atom or a (C 1 -C 3) alkyl;

n represents 0, 1 or 2;

AUc represents a (C 1 -C 4) alkyl, in the base state as well as in the hydrate or solvate state.

Among the compounds of formula (I) which are the subject of the invention, a first group of compounds consists of the compounds for which:

X represents a group -SO- or -SO 2 -;

Ri represents:

. 3-chloropropyl; tert-butyl; 1-ethylpropyl; 1-methylbutyl;

. 3-chlorophenyl; 4- (trifluoromethyl) phenyl; 4-chlorophenyl; a 2-fluorophenyl; 3-fluorophenyl; 4-fluorophenyl; 2,5-dichlorophenyl; 2,6-difluorophenyl; 3,5-difluorophenyl; 3-chloro-4-fluorophenyl; 3-chloro-4-methylphenyl; 4-tert-butylphenyl; 3,5-dimethylphenyl; 3-methoxyphenyl; 3-cyanophenyl; A-cyanophenyl; 2- (trifluoromethyl) phenyl; 3- (trifluoromethyl) phenyl;

. 3- (trifluoromethyl) benzyl;

. a 2-naphthyl;

. a 2-thienyl; 5-chloro-2-thienyl;

. 2- (trifluoromethyl) -5-methyl-3-furyl;

. 2,3-dihydrobenzofuryl;

and / or R2 represents a hydrogen atom;

and / or R3 represents a 4-chlorophenyl; 4-bromophenyl; A-methoxyphenyl; 2,4-dichlorophenyl; and / or R4 represents a 2,4-dichlorophenyl; 4-methoxyphenyl; as well as their hydrates or their solvates.

Among the compounds of the latter group, there may be mentioned compounds of formula (I) for which:

X represents a group -SO- or -SO 2 -;

- Rj represents:

. 3-chloroρroρyl; tert-butyl; 1-ethylpropyl; 1-methylbutyl;

. 3-chlorophenyl; 4- (trifluoromethyl) phenyl; 4-chlorophenyl; a 2-fluorophenyl; 3-fluorophenyl; 4-fluorophenyl; 2,5-dichlorophenyl; 2,6-difluorophenyl; 3,5-difluorophenyl; 3-chloro-4-fluorophenyl; 3-chloro-4-methylphenyl; a 4-tet butylphenyl; 3,5-dimethylphenyl; 3-methoxyphenyl; 3-cyanophenyl; a 4-cyanophenyl; 2- (trifluoromethyl) phenyl; 3- (trifluoromethyl) phenyl;

. 3- (trifluoromethyl) benzyl;

. a 2-naphthyl;

. a 2-thienyl; 5-chloro-2-thienyl;

. 2- (trifluoromethyl) -5-methyl-3-furyl;

. 2,3-dihydrobenzofuryl;

R2 represents a hydrogen atom;

- R3 represents a 4-chlorophenyl; 4-bromophenyl; 4-methoxyphenyl; a

2,4-dichlorophenyl;

R4 represents 2,4-dichlorophenyl; 4-methoxyphenyl; as well as their hydrates or their solvates.

Among the compounds of the latter group, mention may be made of the compounds of formula (I) for which:

Ri represents:

. 3-chloropropyl;

. 3-chlorophenyl; 4- (trifluoromethyl) phenyl;

. 3- (trifluoromethyl) benzyl;

R2 represents a hydrogen atom;

- R3 represents a 4-chlorophenyl; 4-bromophenyl;

R4 represents 2,4-dichlorophenyl; as well as their hydrates or their solvates.

Among the compounds of formula (T) that are subjects of the invention, mention may be made especially of the following compounds: 3-chloro-N - [[4- (4-chloro-phenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] benzenesulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -4- (trifluoromethyl) benzenesulfonamide;

- N - [[4- (4-chlorophenyl) -5- _(2, 4-dichlorophenyl) -2-thienyl] methyl] -l- [3- (trifluoroniéthyl) phenyl] methanesulfonamide;

N - [[4- (4-bromophenyl) -5- (2,4-dichloro-phenyl) -2- [1-yl] methyl] -3-chloropropane-1-sulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -2-methylpropane-2-sulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichloro-phenyl) -2-thienyl] methyl] -2-methylpropane-2-sulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-tbenyl] methyl] pentane-3-sulfonamide;

- N - [[4- (4-chlorophenyl) -5- (2 _J 4-dichlorophenyl) -2-thienyl] methyl] pentane-2-sulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichloro-phenyl) -2-thienyl] methyl] -2-fluorobenzenesulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -3-fluorobenzenesulfonamide;

N - [[4- (4-chloro-phenyl) -5- (2,4-dichloro-phenyl) -2-thienyl] methyl] -4-fluorobenzenesulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -3,5-difluorobenzenesulfonamide;

3-chloro-N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -4-fluorobenzenesulfonamide;

2,5-dichloro-N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] benzenesulfonamide;

4-tert-butyl-N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-tbenyl] methyl] benzenesulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichloro-phenyl) -2-thienyl] methyl] -3- (trifluoromethyl) benzenesulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichloro-phenyl) -2-thienyl] methyl] thiophene-2-sulfonamide;

5-chloro-N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] thiopbene-2-sulfonamide; - K - [[4- (4-Chlorophenyl) -5- (2,4-dichloro-phenyl) -2-thienyl] methyl] -5-methyl-2-

(trifluoromethyl) furan-3-sulfonamide;

N - [[5- (2,4-dichlorophenyl) -4- (4-methoxyphenyl) -2-thienyl] methyl] p-ethyl-3-sulfonamide;

3-chloro-N- [4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] benzenesulfonamide;

4-chloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] benzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -2-fluorobenzenesulfonamide;

N - [[4- (2,4-dichloro-phenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -3-fluorobenzenesulfonamide;

N - [[4- (2,4-dichloro-phenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -4-fluorobenzenesulfonamide;

2,5-dichloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] benzenesulfonamide;

N - [[4- (2,4-dichloro-phenyl) -5- (4-methoxyphenyl) -2-thienyl] -p-ethyl] -2,6-difluorobenzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -3,5-difluorobenzenesulfonamide;

3-chloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methyloxyphenyl) -2-thienyl] methyl] -4-fluorobenzenesulfonamide;

3-chloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxy-phenyl) -2-thienyl] methyl] -4-methylbenzenesulfonamide;

4-tert -butyl-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-tbenyl] methyl] benzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -3,5-dimethylbenzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] ethyl] -3-methoxybenzenesulfonamide;

3-cyano-N - [[4- (2,4-dichloro-phenyl) -5- (4-methoxyphenyl) -2-tbenyl] methyl] benzenesulfonamide;

4-cyano-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-tbenyl] methyl] benzenesulfonamide;

- N - [[4- (2 ₃ 4-dichloroρhényl) -5- (4-méthoxypliényl) -2-thienyl] methyl] -2- (trifluoromethyl) benzenesulfonamide; N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -3- (trifluoromethyl) benzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] naphthalene-2-sulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] thiophene-2-sulfonamide;

5-chloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methyloxyphenyl) -2-thienyl] methyl] thiophene-2-sulfonamide;

N - [[4- (2,4-dichloro-phenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -5-methyl-2- (trifluoromethyl) furan-3-sulfonamide;

N - [[4- (2,4-dichloro-phenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -2,3-dihydrobenzofuran-5-sulfonamide; as well as their hydrates or their solvates.

In what follows, a protective group Pg is understood to mean a group that makes it possible, on the one hand, to protect a reactive function such as a hydroxyl or an amine during a synthesis and, on the other hand, to regenerate the intact reactive function. at the end of synthesis. Examples of protecting groups and methods of protection and deprotection are given in "Protective Group in Organic Synthesis", Green et al., ^2nd Edition (John Wiley & Sons, Inc., New York), 1991.

By leaving group is meant, in what follows, a group that can be easily cleaved from a molecule by breaking a heterolytic bond, with departure from an electronic pair. This group can thus be easily replaced by another group during a substitution reaction, for example. Such leaving groups are, for example, halogens or an activated hydroxy group such as methanesulfonate, benzenesulfonate, p-toluenesulfonate, triflate, acetate, etc. Examples of leaving groups as well as references for their preparation are given in Advances in Organic Chemistry, J. Tuesday, 3 ^rd Edition, Wiley Interscience, 1985, p. 310-316.

According to the invention, the compounds of formula (I) can be prepared according to a process which is characterized in that a compound of formula:

(Π) in which R ₂ , R 3 and R 4 are as defined for a compound of formula (I)

or by a sulfinyl halide of formula:

Wherein R 1 is as defined for a compound of formula (I) and Hal represents a halogen atom when a compound of formula (I) is to be prepared in which -X- represents a group -SO-;

or by a sulphonyl halide of formula:

Hal-SO ₂ -R (III) wherein Ri is as defined for a compound of formula (I) and Hal represents a halogen atom, while to prepare a compound of formula (I) wherein -X- represents a group -SO ₂ -.

When a compound of formula (II) is treated with a sulfinyl halide of formula (XV), the reaction is carried out in the presence of a base such as triethylamine, in a solvent such as dichloromethane and at a temperature comprised between ambient and the reflux temperature of the solvent.

When a compound of formula (II) is treated with a sulfonyl halide of formula (III), the reaction is carried out in the presence of a base such as triethylamine, diisopropylethylamine or 4-dimethylaminopyridine in a solvent such as dichloromethane , tetrahydrofuran, or N, N-dimethylformamide, and at a temperature between 0 ° C and the reflux temperature of the solvent.

According to one variant of the process, the compounds of formula (I) in which -X- represents a group -SO ₂ - can be prepared by reaction of a compound of formula (I) in which -X- represents a group -SO- with an oxidizing agent. As the oxidizing agent, it is possible to use 3-chloroperbenzoic acid in a solvent such as dichloromethane and at a temperature of between 0 ^° C. and room temperature.

According to one variant of the process, a compound of formula (I) in which R ₂ represents a (C 1 -C 3) alkyl may be prepared by reaction of a compound of formula (I) in which R ₂ = H with a halide of -C3) alkyl, in the presence of a base such as sodium hydride, in a solvent such as N, N-dimethylformamide and at a temperature between room temperature and the reflux temperature of the solvent.

The compounds of formula (I) thus obtained may subsequently be separated from the reaction medium and purified by conventional methods, for example by crystallization or chromatography.

The compounds of formula (II) are prepared by reaction of a compound of formula: in which R3 and R4 are as defined for a compound of formula (I) and Y represents a leaving group as defined above, preferably a halogen atom or an activated hydroxy group such as a methanesulfonate group, benzene sulfonate, p-toluenesulfonate or triflate, with a compound of formula:

H ₂ NR ₂ (V) in which R ₂ is as defined for a compound of formula (I).

The reaction is carried out in a solvent such as N, N-dimethylformamide, acetonitrile, dichloromethane, toluene or propan-2-ol, and in the presence or absence of a base. When a base is used, it is chosen from organic bases such as triethylamine, N, N-diisopropylethylamine or N-methylmorpholine. The reaction is carried out at a temperature between 0 ^° C. and the reflux temperature of the solvent.

According to one variant, it is also possible to prepare a compound of formula ( _II ) in which R ₂ = H by reaction of a compound of formula (IV) in which Y = Cl with 1,3,5,7-tetraazatricyclo [3.3 3 '7] decane (or hexamethylenetetramine) followed by hydrolysis with a strong acid such as hydrochloric acid.

According to another variant, it is also possible to prepare a compound of formula (II) in which R ₂ = H by reduction of a compound of formula:

O

II

wherein R3 and R4 are as defined for a compound of formula (I). The reduction is effected by means of a reducing agent such as borane in a solvent such as tetrahydrofuran, at a temperature between room temperature and the reflux temperature of the solvent, followed by acid hydrolysis.

Compounds of formula (III) are commercially available or described in the literature, or may be prepared according to methods described therein such as in J. Org. Chem. USSR, 1970, 6, 2454-2458; J. Am. Chem. Soc., 1952, 74, 2008; J. Med. Chem., 1977, 20 (10), 1235-1239; EP0469984; WO95 / 18105. For example, the compounds of formula (III) can be prepared by halogenation of the corresponding sulfonic acids or their salts, for example their sodium or potassium salts. The reaction is carried out in the presence of a halogenating agent such as phosphorus oxychloride, thionyl chloride, phosphorus trichloride, phosphorus tribromide or phosphorus pentachloride, without solvent or in a solvent such as halogenated hydrocarbon or N, N-dimethylformamide and at a temperature between -10 ⁰ C and 200 ° C.

The compounds of formula (IV) are prepared from compounds of formula:

in which R3 and R4 are as defined for a compound of formula (I), according to conventional methods mentioned above.

Thus, for example, when in a compound of formula (IV), Y represents a halogen atom, a compound of formula (VU) is treated with a halogenating agent such as PC15, PBrc, HBr or BBr3, in a solvent such as dichloromethane and at a temperature between -10 ° C and room temperature.

When, in a compound of formula (IV), Y represents a methanesulphonate, a benzenesulphonate, a p-toluenesulphonate or a trifluoromethanesulphonate, a compound of formula (VTI) is reacted with a sulphonyl chloride of formula W-SO 2 -Cl in W is methyl, phenyl, p-tolyl or trifluoromethyl. The reaction is carried out in the presence of a base such as triethylamine, pyridine or N, N-diisopropylethylamine, in a solvent such as dichloromethane or toluene and at a temperature between -2O ⁰ C and the temperature of reflux of the solvent.

The compounds of formula (V) are known.

The compounds of formula (VI) are prepared by reacting an acid or a functional derivative of this acid of formula:

wherein R3 and R4 are as defined for a compound of formula (I), with ammonia.

The compounds of formula (VI) are prepared by a -reduction reaction of the compounds of formula:

wherein R3 and R4 are as defined for a compound of formula (I) and Z is hydroxy or (C1-C2) alkoxy.

The reaction is carried out in the presence of a reducing agent such as sodium borohydride or lithium aluminum hydride, in a solvent such as tetrahydrofuran, and at a temperature of between -20 ° C. and the temperature room. When a compound of formula (IX) in which Z 2 OH is reduced, the acid may be previously activated by reaction with ethyl chloroformate in the presence of triethylamine.

Compounds of formula (VIII) or compounds of formula (IX) in which Z = OH are prepared by conventional hydrolysis of a compound of formula (IX) in which Z = (C; [- C2) alkoxy.

The reaction is carried out by hydrolysis in an alkaline medium using, for example, an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide in a solvent such as water, methanol, 1,2-dimethoxyethane 1,4-dioxane or a mixture of these solvents and at a temperature between 0 ^° C. and the reflux temperature of the solvent.

The compounds of formula (IX) wherein Z = (C _j -C2) alkoxy are prepared according to Scheme I below.

SCHEME I

O NaHMDS he

R ₃ -CH ₂ -COOH + R ₄ -COOMe R 1 -CH ₂ -CR ₄ al

(X) (XT) (XD)

bl DMF / POCI ₃

(Xm): (Z + E)

cl Z-OC-CH ₂ -SH (XIV)

(IX): Z = (C _r C ₂ ) alkoxy

In step a1 of SCHEME I, the reaction of a compound of formula (X) with a compound of formula (XI) is carried out in the presence of an alkali metal salt of hexamethyldisilazane such as the sodium salt for example, in a solvent such as tetrahydrofuran and at a temperature between -70 ⁰ C and 0 ° C.

In step b_L, the compound of formula (XII) thus obtained is reacted with the mixture N, N-dimethylformamide / phosphorus oxychloride in a solvent such as 1,2-dichloroethane and at a temperature between - 10 ^° C. and the reflux temperature of the solvent.

The compound (XIII) thus obtained is reacted in step c1 with the compound (XIV), in the presence of a base such as 1,8-diazabicyclo [5,4,0] undec-7-ene, in a solvent such as acetonitrile and at a temperature between room temperature and the reflux temperature of the solvent.

The compounds of formula (X), (XI), (XIV) and (XV) are known or prepared according to known methods.

The following EXAMPLES describe the preparation of certain compounds in accordance with the invention. These examples are not limiting and only illustrate the present invention. The numbers of the exemplified compounds refer to those given in TABLE I below, which illustrates the chemical structures and the physical properties of some compounds according to the invention.

In the Preparations and in the Examples the following abbreviations are used: ether: diethyl ether diisopropyl ether

DMSO: dimethylsulfoxide

DMF: N, N-dimethylformamide

THF: tetrahydrofuran

TBTU: 2- (7H-benzotriazol-1-yl) -1,1,3,3-tetramethyluronium tetrafluoroborate

DCM: dichloromethane

AcOEt: ethyl acetate

DIPEA: diisopropylethylamine

DBU: 1,8-diazabicyclo [5.4.0] undec ~ 7-ene

TFA: trifluoroacetic acid

2N hydrochloric ether: 2N solution of hydrochloric acid in diethyl ether

F: melting point

TA: room temperature

Eb: boiling temperature

HPLC: high performance liquid chromato graphy

Silica H: silica gel 60 H marketed by Merck (DARMSTAD)

Buffer solution pH = 2: solution of 16.66 g of KHSO4 and 32.32 g of K2SO4 in 1 liter of water.

Proton nuclear magnetic resonance spectra ( ¹ H NMR) are recorded at 200 MHz in DMSO-dg. The chemical shifts δ are expressed in parts per million (ppm). For the interpretation of spectra, the following abbreviations are used: s: singlet, d: doublet, t: triplet, q: quadruplet, qt: quintuplet, m: massive, rnt: multiplet, se: expanded singlet, dd: doublet doubled .

The compounds according to the invention are analyzed by LC / UV / MS coupling (liquid chromato graphy / UV detection / mass spectrometry). The molecular peak (MH) and the retention time (tr) are measured in minutes.

Method 1:

A symmetry C18 column of 2.1 × 50 mm, 3.5 μm, is used at 30 ^° C., flow rate 0.4 ml / minute.

The eluent is composed as follows: solvent A: 0.005% trifluoroacetic acid (TFA) in water at pH 3.15; solvent B: 0.005% TFA in acetonitrile. Gradient:

The UV detection is carried out at λ = 210 nM and the mass detection in ESI positive chemical ionization mode.

Method 2:

An XTerra MS C18 column of 2.1 x 50 mm, 3.5 μm, is used at 30 ° C, flow rate 0.4 ml / minute.

The eluent is composed as follows: - solvent A: 10 mM ammonium acetate (ACONH4) in water at pH 7; solvent B: acetonitrile.

Gradient:

The UV detection is carried out at λ = 220 nM and the mass detection in ESI positive chemical ionization mode.

Method 3:

An XTerra MS Cl 8 column of 2.1 x 50 mm is used; 3.5 μm; at 30 ^° C., flow rate 0.4 ml / minute.

The eluent is composed as follows:

solvent A: 10 mM ammonium acetate (ACONH4) in water at pH 7;

solvent B: acetonitrile

Gradient:

Method 4:

An XTerra MS C18 column of 2.1 x 30 mm is used; 3.5 μm; at 30 ° C., flow rate 0.8 ml / minute.

The eluent is composed as follows: solvent A: 0.025% trifluoroacetic acid (TFA) in water; solvent B: 0.025% of TFA in acetonitrile;

Gradient:

UV detection is performed by an iodine bar detector between 210 and 400 nM and ESI positive chemical ionization mass detection.

PREPARATIONS

1. Preparations of the compounds of formula (XII):

Preparation 1.1

2- (4-Chlorophenyl) -1- (2,4-dichlorophenyl) ethanone.

420 ml of a 2M solution of the sodium salt of hexamethyldisilazane in THF are cooled to -60 ^° C. under a nitrogen atmosphere, 350 ml of THF are added, then a solution of 57.6 is added dropwise. 4-chlorophenylacetic acid in 70 ml of THF and stirred for 1 hour at -60 ° C. 66 g of methyl 2,4-dichlorobenzoate are then added dropwise at -60 ^° C., the mixture is left stirring for 40 minutes at -60 ^° C. and then the temperature is allowed to rise to 0 ^° C. The reaction mixture is poured into the reaction mixture. on an ice / 1 liter mixture of 2N HCl, extracted with ether, the organic phase is dried over Na 2 SO 4, the solvent is concentrated under vacuum to a volume of 150 ml, 200 ml of pentane are added and the crystallized product formed is filtered off with suction. . 60 g of the expected compound are obtained.

Preparation 1.2

2- (4-Bromophenyl) -1- (2,4-dichlorophenyl) ethanone.

436 ml of a 2M solution of the sodium salt of hexamethyldisilazane in THF are cooled to -60 ^° C. under a nitrogen atmosphere, 400 ml of THF are added, then a solution of 75 g of toluene is added dropwise. 4-bromophenylacetic acid in 100 ml of THF and left stirring for 1 hour 30 minutes at -70 ° C. 67.9 g of methyl 2,4-dichlorobenzoate are then added dropwise, the mixture is stirred for 30 minutes and then the temperature is allowed to rise to 5 ^° C. The reaction mixture is poured into an ice / 1 liter mixture of 2N HCl, extracted with ether, the organic phase washed with saturated NaHCO 3 solution, with water, dried over Na 2 SO 4 and the solvent evaporated under vacuum to a volume of 200 ml, pentane added and the product filtered off crystallized formed. 80 g of the expected compound are obtained.

Preparation 1.3 1- (2,4-Dichlorophenyl) -2- (4-methoxyphenyl) ethanone.

413 ml of a 2M solution of the sodium salt of hexamethyldisilazane in THF are cooled to -65 ° C., under a nitrogen atmosphere, 300 ml of THF are added, then a solution of 55 g of toluene is added dropwise. 4-methoxyphenylacetic acid in 70 ml of THF and stirred for 3 hours at a temperature below -45 ° C. 64.5 g of methyl 2,4-dichlorobenzoate are then added dropwise and the mixture is left stirring, allowing the temperature to rise to 0 ° C. The reaction mixture is poured into ice / 1 liter 2N HCl, extracted with ether, the organic phase washed with saturated NaHCO 3 solution, dried over Na 2 SO 4 and the solvent evaporated in vacuo. The residue is chromatographed on silica gel, eluting with heptane and then with the heptane / AcOEt mixture to (90/10; v / v). 29 g of the expected compound are obtained.

2. Preparations of the compounds of formula (XIII):

Preparation 2.1

3-Chloro-2- (4-chlorophenyl) -3- (2,4-dichlorophenyl) acrolein.

A solution of 28.7 ml of DMF in 60 ml of 1,2-dichloroethane is cooled down to -5 ° C., 30 ml of POCl3 are added dropwise and the mixture is left stirring while allowing the temperature to rise to RT. A solution of 30 g of the compound obtained in Preparation 1.1 in 300 ml of 1,2-dichloroethane is then added and the mixture is heated at 60 ^° C. overnight. After cooling, the reaction mixture is poured into ice, the pH is brought to 7 by addition of NaHCO 3, extracted with DCM, the organic phase is dried over Na 2 SO 4 and the solvent is evaporated under vacuum. 35 g of the expected compound are obtained.

Preparation 2.2

2- (4-Bromophenyl) -3-chloro-3- (2,4-dichlorophenyl) acrolein.

A solution of 33.7 ml of DMF in 75 ml of 1,2-dichloroethane is cooled down to -5 ^° C., 40.6 ml of POCl3 are added dropwise and the mixture is left stirring while allowing the temperature to rise to RT. A solution of 40 g of the compound obtained in Preparation 1.2 in 300 ml of 1,2-dichloroethane is then added and heated to reflux for 48 hours. After cooling, the reaction mixture is poured into 1.5 liters of ice water, the pH is brought to 7 by addition of NaHCO 3, extracted with DCM, the organic phase is dried over Na 2 SO 4 and the solvent is evaporated under vacuum. The residue is chromatographed on silica gel eluting with the gradient of the heptane / DCM mixture from (90/10; v / v) to (50/50; v / v). 39 g of the expected compound are obtained.

Preparation 2.3

3-Chloro-3- (2,4-dichlorophenyl) -2- (4-methoxyphenyl) acrylaldehyde.

A solution of 36.9 ml of DMF in 70 ml of 1,2-dichloroethane is cooled to 0-5 ° C., 41 ml of POCl3 are then added dropwise and the mixture is left stirring, allowing the temperature to rise to RT. A solution of 20 g of the compound obtained in Preparation 1.3 in 200 ml of 2-dichloroethane is then added and then heated at 40 ^° C. overnight and at reflux for 4 hours. After cooling, the reaction mixture is poured onto ice, basified by addition of sodium acetate, extracted with DCM, the organic phase is dried over Na 2 SO 4 and the solvent is evaporated off under vacuum. The residue is chromatographed on silica gel, eluting with DCM. 25 g of the expected compound are obtained.

3. Preparations of the compounds of formula (IX):

Preparation 3.1

Methyl 4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) thiophene-2-carboxylate.

To a solution of 33 g of the compound obtained in Preparation 2.1 in 300 ml of acetonitrile is added 8.53 ml of methyl mercaptoacetate and then 10.51 ml of DBU and left stirring overnight at RT. The crystallized product formed is filtered off and dried under vacuum. 22 g of the expected compound are obtained.

Preparation 3.2

Methyl 4- (4-bromophenyl) -5- (2,4-dichlorophenyl) thiophene-2-carboxylate.

To a solution of 39 g of the compound obtained in Preparation 2.2 in 300 ml of acetonitrile is added 26.8 ml of methyl mercaptoacetate and then 45.5 ml of DBU and stirred overnight at RT. The precipitated product formed is filtered off and dried under vacuum. 13 g of the expected product are obtained.

Preparation 3.3

Methyl 5- (2,4-dichlorophenyl) -4- (4-methoxyphenyl) thiophene-2-carboxylate.

A mixture of 10 g of the compound of Preparation 2.3 and 5.76 ml of methyl mercaptoacetate in 100 ml of acetonitrile is heated to 45 ° C., 4.84 ml of DBU is added dropwise and the mixture is left stirring and allowed to return. the temperature at room temperature. The reaction mixture is concentrated under vacuum, the residue is taken up in a 0.5N HCl solution and extracted with ether, and the organic phase is dried over. Na 2 SO 4 and the solvent evaporated in vacuo. The residue is chromatographed on silica gel eluting with heptane and then with the heptane / AcOEt mixture to (80/20; v / v). 6.8 g of the expected compound are obtained.

4. Preparation of compounds of formula (VII): Preparation 4.1 [4- (4-Chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methanol.

Cooled to -20 ⁰ C a suspension of 1.43 g of aluminum hydride, of ^lithium in 100 ml of THF, added dropwise a solution of 10 g of the compound obtained in Preparation 3.1 in 20 ml of THF and stirred for 1 hour at -20 ^° C. The reaction mixture is hydrolyzed by addition of water until a white haze appears, filter the inorganic salts on Celite and the filtrate concentrated in vacuo. The residue is taken up in pentane, stirred and the crystalline product formed. 7 g of the expected compound are obtained.

5. Preparations of compounds of formula (IV): Preparation 5.1 5- (Chloromethyl) -3- (4-chlorophenyl) -2- (2,4-dichlorophenyl) thiophene.

A solution of 7 g of the compound obtained in Preparation 4.1 in 80 ml of DCM is cooled to -10 ° C., 4.14 g of PCI5 is added and the mixture is left stirring for 24 hours, allowing the temperature to rise to RT. Water is added to the reaction mixture, stirred for 15 minutes, extracted with AcOEt, the organic phase dried over Na 2 SO 4 and the solvent evaporated in vacuo. The residue is taken up in pentane, stirred and the crystalline product formed. 6.8 g of the expected compound are obtained.

6. Preparations of compounds of formula (VIII) Preparation 6.1

4- (4-Bromophenyl) -5- (2,4-dichlorophenyl) thiophene-2-carboxylic acid.

To a mixture of 16 g of the compound obtained in Preparation 3.2 in 80 ml of 1,2-dimethoxyethane and 40 ml of MeOH is added 24 ml of a 30% NaOH solution and left stirring for 2 hours at RT. The reaction mixture is concentrated under vacuum, the residue is extracted with water, the aqueous phase is washed with ether and the aqueous phase is acidified to pH 2 by addition of a 30% solution of HCl, extracted with water. AcOEt, dried the organic phase over MgSO 4 and evaporated the solvent in vacuo. 12.4 g of the expected compound are obtained after crystallization from iso ether.

Preparation 6.2

5- (2,4-dichlorophenyl) -4- (4-methoxyphenyl) thiophene-2-carboxylic acid.

A mixture of 10 g of the compound obtained in Preparation 3.3 and 2.1 g of KOH in 50 ml of 1,2- dimethoxyethane and 100 ml of 95% EtOH. The reaction mixture is concentrated under vacuum, the residue is extracted with water, the aqueous phase is washed with ether and the aqueous phase is acidified to pH 2 by addition of a solution of 30% HCl extracted with ether. The organic phase is dried over NaSO 4 and the solvent is evaporated under vacuum. The residue is taken up in iso ether, pentane is added and the crystalline product formed is filtered off. 7.5 g of the expected compound are obtained.

7. Preparations of compounds of formula (VI) Preparation 7.1 4- (4-Bromophenyl) -5- (2,4-dichlorophenyl) thiophene-2-carboxamide.

A mixture of 14 g of the compound obtained in Preparation 6.1 and 8.35 ml of thionyl chloride in 140 ml of 1,2-dichloroethane is refluxed for 2 hours; The reaction mixture is concentrated under vacuum, the residue is taken up in 1,2-dichloroethane and the solvent is evaporated off under vacuum. The acid chloride thus formed is taken up in 150 ml of DCM and this solution is added dropwise to a mixture of 32 ml of a 2M solution of ammonia in MeOH and 4.4 ml of triethylamine and then left for 30 minutes. with stirring. It is concentrated under vacuum and 13.6 g of the expected compound are obtained after crystallization in water and drying under vacuum.

Preparation 7.2

5- (2,4-dichlorophenyl) -4- (4-methoxyphenyl) thiophene-2-carboxamide.

A mixture of 7.5 g of the compound obtained in Preparation 6.2 and 7.22 ml of thionyl chloride in 100 ml of 1,2-dichloroethane is refluxed for 3 hours; The reaction mixture is concentrated under vacuum, the residue is taken up in toluene and the solvent is evaporated off under vacuum. The acid chloride thus formed is taken up in 20 ml of DCM and this solution is added dropwise to a mixture of 28.3 ml of a 2M solution of ammonia in MeOH and 4 ml of triethylamine in 30 ml of DCM. previously cooled to 0-5 ° C, then left stirring allowing the temperature to rise to room temperature. The reaction mixture is concentrated under vacuum, the residue is taken up in a 0.5N HCl solution and extracted with ether / AcOEt mixture, the organic phase is dried over Na 2 SO 4 and the solvents are evaporated under vacuum. The residue is taken up in an ether / iso ether mixture and the precipitate formed is filtered off with suction. 6 g of the expected compound are obtained.

8. Preparations of the compounds of formula (II): Preparation 8.1.

1- [4- (4-Chloro-phenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methanamine hydrochloride. A mixture of 6.8 g of the compound obtained in Preparation 5.1, 2.75 g of sodium iodide and 2.95 g of hexamethylenetetramine in 100 ml of EtOH is stirred for 48 hours at RT and then heated to 60.degree. ⁰ C for 3 hours. 28 ml of concentrated HCl are then added and refluxed for 1 hour. The reaction mixture is filtered and the filtrate concentrated in vacuo. The residue is taken up in 100 ml of ether, 100 ml of water are added, the mixture is stirred for 30 minutes and the precipitate formed is filtered off with suction. 7 g of the expected compound are obtained.

Preparation 8.2

1- [4- (4-Bromophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methanamine hydrochloride.

To a solution of 13.5 g of the compound obtained in Preparation 7.1 in 35 ml of THF, 150 ml of an IM solution of borane in THF are added and the mixture is refluxed for 2 hours. After cooling to RT, 40 ml of MeOH are added dropwise. The reaction mixture is cooled to 50 ^° C., 16 ml of 2N hydrochloric ether are added dropwise, the mixture is stirred overnight at RT and the crystallized product formed is filtered off with suction. 8.2 g of the expected compound are obtained.

Preparation 8.3

1- [5- (2,4-Dichlorophenyl) -4- (4-methoxyphenyl) -2-thienyl] methanamine hydrochloride.

To a solution of 6 g of the compound obtained in Preparation 7.2 in 60 ml of THF, 63.5 ml of an IM solution of borane in THF are added and the mixture is refluxed for 4 hours. After cooling to room temperature, MeOH is added dropwise until the evolution of gas ceases. The reaction mixture is cooled to 5 ° C., 20 ml of 2N hydrochloric ether are added and the mixture is left stirring for 30 minutes. The reaction mixture is concentrated under vacuum to a volume of 15 ml, which is added dropwise to an ether / iso ether mixture (70/70 v / v) and the precipitate formed is filtered off with suction. 3 g of the expected compound are obtained.

Preparation 8.4

1- [4- (2,4-Dichlorophenyl) -5- (4-methoxyphenyl) -2-tolylene] methanamine hydrochloride.

This compound is prepared following the procedures described successively in Preparations 1.3, 2.3, 3.3, 6.2, 7.2 and 8.3.

9. Preparations of compounds of formula (ITT):

Preparation 9.1

Pentane-3-sulphonyl chloride. A. 1-Ethylpropyl imidothiocarbamate.

A mixture of 15 g of thiourea, 82 g of pentan-3-ol and 50 ml of a 47% solution of HBr in water is refluxed for 4 days. The reaction mixture is concentrated under vacuum, the residue is taken up several times with water and concentrated in vacuo each time until the excess pentan-3-ol is removed. 44 g of the expected compound are obtained, which is used as such.

B. Pentane-3-thiol.

A solution of 44 g of the compound expected in the preceding stage in 150 ml of water is heated to 60 ^° C. and a concentrated solution of NaOH is slowly added until the two phases are formed in the reaction mixture. The mixture is extracted with ether and the organic phase is dried over Na.sub.2SO.sub.4 and the solvent is evaporated under vacuum. 10 g of the expected compound are obtained, which is used as such.

C- pentane-3-sulphonyl chloride.

To a mixture of 10 g of the compound obtained in the preceding step and 40 ml of acetic acid, 20 g of ice are added then bubbled chlorine gas to saturation and stirred at 0-5 ° C until to discoloration of the reaction mixture. Extracted with ether, the organic phase is washed several times with 5% Na 2 S 2 O 3 solution, with water, dried over Na 2 SO 4 and the solvent is evaporated under vacuum. 7 g of the expected compound are obtained. EXAMPLE 1 Compound No. 1

3-Chloro-N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] benzenesulfonamide.

0.53 ml of triethylamine and then 0.274 g of 3-chlorobenzenesulphonyl chloride are added to a solution of 0.5 g of the compound obtained in Preparation 8.1 in 30 ml of DCM and the mixture is stirred overnight at RT. The reaction mixture is concentrated under vacuum, the residue is taken up in water and extracted with AcOEt, the organic phase is dried over Na 2 SO 4 and the solvent is evaporated under vacuum. The residue is chromatographed on silica gel, eluting with heptane and then with the gradient of the heptane / AcOEt mixture to (10/10; v / v). 0.47 g of the expected compound is obtained. EXAMPLE 2 Compound No. 5

N - [[4- (4-chloro-phenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -2-methylpropane-2-sulfinamide.

To a solution of 0.35 g of the compound obtained in Preparation 8.1 in 20 ml of DCM is added 0.36 ml of triethylamine and then 0.15 g of 2-methylpropane-2-sulfinyl chloride and left overnight with stirring. ambient temperature. The reaction mixture is concentrated under vacuum, the residue is taken up with 1N HCl solution, extracted with the ether dries the organic phase over Na 2 SC 4 and evaporates the solvent in vacuo. The residue is taken up in ether, iso ether added, and the crystalline product formed is filtered off. 0.22 g of the expected compound is obtained. EXAMPLE 3 Compound No. 6

N - [[4- (4-Chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -2-methylprop an-2-sulfonamide.

A mixture of 0.3 g of compound No. 5 and 0.27 g of 3-chloroperbenzoic acid in 20 ml of DCM is left stirring for 1 hour at room temperature. The reaction mixture is concentrated under vacuum, the residue is taken up with a 10% solution of NaHCO 3, extracted with ether, the organic phase is dried over Na 2 SO 4 and the solvent is evaporated under vacuum. The residue is chromatographed on silica gel, eluting with DCM. 0.2 g of the expected compound is obtained after crystallization from iso ether. EXAMPLE 4: Compound No. 7

N - [[4- (4-Chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] pentane-3-sulfonamide.

A mixture of 0.5 g of the compound obtained in Preparation 8.1, 0.69 ml of triethylamine, 0.25 g of the compound obtained in Preparation 9.1 and 0.15 g of stirring is stirred overnight at 0 ° -5 ° C. 4-dimethylaminopyridine in 20 ml of DCM. 0.25 g of the compound of Preparation 9.1 are added and the mixture is left stirring for 5 hours while allowing the temperature to rise to ambient temperature. The reaction mixture is concentrated under vacuum, the residue is taken up in water and extracted with ether, the organic phase is dried over Na 2 SO 4 and the solvent is evaporated off under vacuum. The residue is chromatographed on silica gel, eluting with a DCM / AcOEt mixture (95/5, v / v). 0.08 g of the expected compound is obtained. EXAMPLE 5 Compound No. 20

N - [[5- (2,4-dichlorophenyl) -4- (4-methyleneoxyphenyl) -2-thienyl] methyl] pentane-3-sulfonamide. ,

A mixture of 0.6 g of the compound obtained in Preparation 8.3, 0.6 ml of triethylamine, 0.38 g of the compound obtained in Preparation 9.1 and 0.18 g of EtOH is stirred overnight at 0 ° -5 ° C. 4-dimethylaminopyridine in 20 ml of DCM. 0.238 g of the compound of Preparation 9.1 are added and the mixture is stirred for 2 hours at room temperature. The reaction mixture is concentrated under vacuum, the residue is taken up in water and extracted with AcOEt, the organic phase is dried over Na 2 SO 4 and the solvent is evaporated under vacuum. The residue is chromatographed on silica gel, eluting with heptane and then with the heptane / AcOEt mixture to (70/30; v / v). 0.15 g of the expected compound is obtained. EXAMPLE 6 Compound Nos. 9 to 19, 21 to 42 The compounds of formula (I) in which X = -SO 2 - are prepared by combinatorial chemistry according to the method described below:

The compounds of formula (II) (Preparation 8.1 or 8.4) are dissolved in DMF at the concentration of ₅ M in the presence of 3 equivalents of DIPEA. 300 ml of these solutions are placed in each 2 ml well and 120 μl of a solution containing the corresponding compound of formula (III) in THF are added at a concentration of 0.25 M. The plates are stirred at room temperature for 16 hours. hours then evaporate. The products formed in each well are dissolved by addition of 500 μl of AcOEt, 400 μl of 0.1 M Na 2 CO 3 are added and the plates are agitated. After decantation, 430 μl of aqueous phase are discarded, 300 μl of 5% NaCl are added and the plates are stirred. After decantation, 350 μl of aqueous phase are discarded and the compounds are analyzed by LC / UV / MS by taking 20 μl. The expected compounds are obtained by vacuum evaporation of the rest of the solution.

The following table illustrates the chemical structures and the physical properties of some examples of compounds according to the invention.

In this table :

the "Method" column represents one of the analysis methods used to determine the molecular peak MH ⁺ (or MNH4 if specified) and the retention time as described above,

"-" means that the compound is not observed in mass spectrometry and the tr corresponds to the tr of the majority peak.

- Me represents a methyl group.

TABLE I

: se: IH.

Compound No. 2: ¹ H NMR: DMSO-d ₆ : δ (ppm): 4.35: s: 2H; 6.9-8.1: m: 12H; 8.7

: se: IH.

Compound No. 3: ¹ H NMR: DMSO-d ₆ : δ (ppm): 4.38: d: 2H; 4.57: s: 2H; 7.1-7.8: m: 12H; 8.01: t: 1H.

Compound No. 4: ^1H NMR: DMSO-d _6: δ (ppm): 2.10: qt: 2H; 3.15: mt: 2H; 3.70: t: 2H; 4.40: d: 2H; 7.06: d: 2H; 7.26: s: 1H; 7.36-7.60: m: 4H; 7.71: d: 1H;

8.01: t: 1H.

Compound No. 5: ¹ H NMR: DMSO-d ₆ : δ (ppm): 1.16: s: 9H; 4.41: mt: 2H; 6.08: t: 1H; 7.13: d: 2H; 7.26: s: 1H; 7.35: d: 2H; 7.40: d: 1H; 7.47: dd: 1H;

7.69: d: 1H.

Compound No. 6: ¹ H NMR: DMSO-d ₆ : δ (ppm): 1.30: s: 9H; 4.45: d: 2H; 7.13: d:

2H; 7.23: s: 1H; 7.36: d: 2H; 7.45: s: 1H; 7.36: d: 1H; 7.70: d: 1H; 7.74: t:

IH.

Compound No. 7: ^1H NMR: DMSO-d _6: δ (ppm): 0.94: t: 6H; 1.45-1.95: m: 4H;

2.72: mt: 1H; 4.38: s: 2H; 7.12: d: 2H; 7.25: s: 1H; 7.30-7.44: m: 3H; 7.48: dd: 1H; 7.71: d: 1H; 7.85: s: 1H. Compound No. 20: ¹ H NMR: DMSOd _6: δ (ppm): 0.93: t: 6H; 1.46-1.96: m: 4H; 2.71: mt: 1H; 3.70: s: 3H; 4.37: d: 2H; 6.84: d: 2H; 7.04: d: 2H; 7.20: s: 1H; 7.37: d: 1H; 7.46: dd: 1H; 7.70; d: 1H; 7.84: t: 1H.

The compounds of formula (I) have a very good in vitro affinity (IC 50 ≤ 5.10 ^"7 M) for cannabinoid CB 1 receptors, under the experimental conditions described by M. Rinaldi-Carmona et al (FEBS Letters, 1994, 350, 240-244).

The antagonistic nature of the compounds of formula (I) has been demonstrated by the results obtained in the models of adenylate cyclase inhibition as described in M. Bouaboula et al, J. Biol. Chem., 1995, 270, 13973-13980, M. Rinaldi-Carmona et al., J. Pharmacol. Exp. Ther., 1996, 278, 871-878 and M. Bouaboula et al, J. Biol. Chem., 1997, 272, 22330-22339.

The toxicity of the compounds of formula (I) is compatible with their use as a medicament.

Thus, according to another of its aspects, the subject of the invention is medicaments which comprise a compound of formula (I), or a solvate or a hydrate of the compound of formula (I).

Thus, the compounds according to the invention can be used in humans or animals, in the treatment or prevention of diseases involving cannabinoid CB 1 receptors.

For example and without limitation, the compounds of formula (I) are useful as psychotropic drugs, especially for the treatment of psychiatric disorders including anxiety, depression, mood disorders, insomnia, delusional disorders , obsessive-compulsive disorder, psychosis in general, schizophrenia, attention deficit and hyperactivity disorder (ADHD) in hyperkinetic children (BDM), and the treatment of disorders related to the use of psychotropic substances, particularly in the case of substance abuse and / or substance dependence, including alcohol dependence and nicotine addiction.

The compounds of formula (I) according to the invention can be used as medicaments for the treatment of migraine, stress, psychosomatic diseases, panic attacks, epilepsy, movement disorders , especially dyskinesias or Parkinson's disease, tremors and dystonia.

The compounds of formula (I) according to the invention can also be used as medicaments in the treatment of memory disorders, cognitive disorders, especially in the treatment of senile dementia, Alzheimer's disease, as well as in the treatment of attention disorders or vigilance. In addition, the compounds of formula (I) may be useful as neuroprotective agents, in the treatment of ischemia, head trauma and the treatment of neurodegenerative diseases: including chorea, Huntington's chorea, Tourrette's syndrome.

The compounds of formula (I) according to the invention can be used as medicaments in the treatment of pain: neuropathic pain, acute peripheral pain, chronic pain of inflammatory origin.

The compounds of formula (I) according to the invention can be used as medicaments in the treatment of appetite disorders, palatability (for sugars, carbohydrates, drugs, alcohols or any appetizing substance) and / or conduits. for the treatment of obesity or bulimia as well as for the treatment of type II diabetes or non-insulin-dependent diabetes and for the treatment of dyslipidemia, metabolic syndrome. Thus, the compounds of formula (I) according to the invention are useful in the treatment of obesity and the risks associated with obesity, in particular cardiovascular risks. In addition, the compounds of formula (I) according to the invention can be used as medicaments in the treatment of gastrointestinal disorders, diarrheal disorders, ulcers, vomiting, bladder and urinary disorders, endocrine, cardiovascular disorders, hypotension, hemorrhagic shock, septic shock, chronic cirrhosis of the liver, fatty liver, steatohepatitis, asthma, Raynaud's syndrome, glaucoma , disorders of fertility, premature termination of pregnancy, inflammatory phenomena, diseases of the immune system, especially autoimmune and neuroinflammatory such as rheumatoid arthritis, reactive arthritis, diseases causing demyelination, multiple sclerosis in plaque, infectious and viral diseases such as encephalitis, stroke and as drugs for chemotherapy. anticancer therapy, for the treatment of Guillain-Barré syndrome and for the treatment of osteoporosis.

According to the present invention, the compounds of formula (I) are particularly useful for the treatment of psychotic disorders, in particular schizophrenia, attention deficit and hyperactivity disorder (ADHD) in hyperkinetic children (BDM). ; for the treatment of appetite and obesity disorders; for the treatment of memory and cognitive deficits; for the treatment of alcohol dependence, nicotine addiction, ie for alcohol withdrawal and smoking cessation.

According to one of its aspects, the present invention relates to the use of a compound of formula (I), and their solvates or hydrates for the treatment of the disorders and diseases indicated above.

According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, a solvate or hydrate of said compound, as well as at least one pharmaceutically acceptable excipient.

Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.

In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of formula (I) above, or its solvate or hydrate, may be administered in unit dosage form, in admixture with conventional pharmaceutical excipients, to animals and humans for the prophylaxis or treatment of the above disorders or diseases.

Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration. by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants. For topical application, the compounds according to the invention can be used in creams, gels, ointments or lotions.

By way of example, a unitary form of administration of a compound according to the invention in tablet form may comprise the following components:

Compound according to the invention 50.0 mg Mannitol 223.75 mg

Croscarmellose sodium 6.0 mg Corn starch 15.0 mg Hydroxypropyl methylcellulose 2.25 mg Magnesium stearate 3.0 mg Orally, the dose of active ingredient administered per day can reach 0.01 to 100 rαg / kg, in one or more doses, preferably 0.02 to 50 mg / kg.

There may be special cases where higher or lower dosages are appropriate; such dosages are not outside the scope of the invention. According to the usual practice, the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.

The present invention, according to another of its aspects, also relates to a method of treatment of the above-mentioned pathologies which comprises administering to a patient an effective dose of a compound according to the invention, or a of its hydrates or solvates.

Claims

1. Compound corresponding to formula (I):

in which :

X represents a group -SO- or -SO 2 -;

- R \ represents:

. a (C1-C7) alkyl;

. a non-aromatic carbocyclic radical (C3-C12) ^{unsubstituted} or substituted one or more times by (Ci-C4) alkyl;

. a (C 3 -C 7) cycloalkylmethyl which is unsubstituted or substituted one or more times on the carbocycle by a (C 1 -C 6) alkyl;

. an unsubstituted or mono-, di- or tri-substituted phenyl with substituents independently selected from a halogen atom, a (C 1 -C 4) alkyl, a

C4) alkoxy, (Ci-C4) alkylamino, di- (Ci-C4) alkylamino, cyano, trifluoromethyl, trifluoromethoxy, a group S (O) _n Alk group ₅ a (Ci-C4) alkylcarbonyl ; or from a phenyl, phenoxy, pyrrolyl, imidazolyl, pyridyl or pyrazolyl radical, said radicals being unsubstituted or substituted one or more times by a (C 1 -C 4) alkyl;

. benzyl which is unsubstituted or mono- or disubstituted on phenyl by substituents independently selected from a halogen atom, a

C4) alkyl, (Ci-C4) alkoxy, trifluoromethyl or alpha-substituted by one or two identical or different groups selected from (C _[-C4) alkyl, (C3-C7) cycloalkyl;

. phenethyl which is unsubstituted or mono- or disubstituted on phenyl by substituents independently selected from a halogen atom, a

C4) alkyl, a (C1-C4) alkoxy, a trifluoromethyl radical;

. unsubstituted or mono- or disubstituted naphthyl with substituents independently selected from (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy, trifluoromethyl;

. a benzhydryl; benzhydrylmethyl; . an aromatic heterocyclic radical chosen from pyrrolyl, imidazolyl, furyl, thienyl, pyrazolyl, indolyl, 2,3-dihydrobenzofuryl which is unsubstituted or substituted one or more times with substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a trifluoromethyl radical;

R 2 represents a hydrogen atom or a (C 1 -C 3) alkyl group;

R 3 represents an unsubstituted or mono-, di- or trisubstituted phenyl by substituents independently selected from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy, a trifluoromethyl radical or a group S (O) _n AIk;

n represents 0, 1 or 2;

- Alk represents a (C1-C4) alkyl; as well as their hydrate or solvate.

2. Compound of formula (I) according to claim 1 wherein -X- represents a radical -SO- and the substituents R ^ to R4 are as defined for the compounds of formula (I) in claim 1; as well as their hydrate or solvate.

3. Compound of formula (I) according to claim 1 wherein -X- represents a radical -SO2- and the substituents K \ to R4 are as defined for the compounds of formula (I) in claim 1; as well as their hydrate or solvate.

4. Compound of formula (I) according to claim 1 wherein:

X represents a group -SO- or -SO 2 -;

- Rj represents:

. 3-chloropropyl; tert-butyl; 1-ethylpropyl; 1-methylbutyl; . 3-chlorophenyl; 4- (trifluoromethyl) phenyl; 4-chlorophenyl; a 2-fluorophenyl; 3-fluorophenyl; 4-fluorophenyl; 2,5-dichlorophenyl; 2,6-difluorophenyl; 3,5-difluorophenyl; 3-chloro-4-fluorophenyl; 3-chloro-4-methylphenyl; 4-Fert -butylphenyl; 3,5-dimethylphenyl; 3-methoxyphenyl; 3-cyanophenyl; a 4-cyanophenyl; 2- (trifluoromethyl) phenyl; 3- (trifluoromethyl) phenyl; . 3- (trifluoromethyl) benzyl; o

. a 2-naphthyl;

. a 2-thienyl; 5-chloro-2-thienyl; . 2- (trifluoromethyl) -5-methyl-3-furyl; . 2,3-dihydrobenzofuryl;

- R.2 represents a hydrogen atom;

- R3 represents a 4-chlorophenyl; 4-bromophenyl; 4-methoxyphenyl; 2,4-dichlorophenyl;

R4 represents 2,4-dichlorophenyl; 4-methoxyphenyl; as well as their hydrate or solvate.

5. Compound of formula (I) according to claim 1 wherein:

- Rj represents:

. 3-chloropropyl;

. 3-chlorophenyl; 4- (trifluoromethyl) phenyl;

. 3- (trifluoromethyl) benzyl;

R2 represents a hydrogen atom;

- R3 represents a 4-chlorophenyl; 4-bromophenyl;

R4 represents 2,4-dichlorophenyl; as well as their hydrate or solvate.

6. Compound of formula (I) according to claim 1 selected from: - 3-chloro-N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] benzenesulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -4- (trifluoromethyl) benzenesulfonanide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -1- [3- (trifluoromethyl) phenyl] methanesulfonamide; N - [[4- (4-bromophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -3-chloropropane-1-sulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichloro-phenyl) -2-thienyl] methyl] -2-methylpropane-2-sulfinamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] pentane-3-sulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] pentane-2-sulfonamide; N - [[4- (4-chloro-phenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -2-fluorobenzenesulfonamide;

^"- N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] inéthyl] -3-fluorobenzenesulfonamide;

N - [[4- (4-chloro-phenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -4-fluorobenzenesulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-tbenyl] methyl] -3,5-difluorobenzenesulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -3- (trifluoronethyl) benzenesulfonamide;

5-chloro-N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] thiophene-2-sulfonamide;

N - [[4- (4-chlorophenyl) -5- (2,4-dichlorophenyl) -2-thienyl] methyl] -5-methyl-2- (trifluoromethyl) furan-3-sulfonamide;

N - [[5- (2,4-dichlorophenyl) -4- (4-methoxyphenyl) -2-tbenyl] methyl] pentane-3-sulfonamide;

3-chloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] benzenesulfonamide;

2,5-dichloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] benzenesulfonamide; - N - [[4- (2 ₅ 4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -2,6 "difluorobenzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] ethyl] -3,5-difluorobenzenesulfonamide;

3-chloro-N - [[4- (2,4-dichloro-phenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -4-fluorobenzenesulfonamide;

3-chloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -4-methylbenzenesulfonamide;

4-tert-butyl-N - [[4- (2,4-dichloro-phenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] benzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -3-methoxybenzenesulfonamide;

3-cyano-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] benzenesulfonamide;

4-cyano-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] benzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -2- (trifluoromethyl) benzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -3- (trifluoromethyl) benzenesulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] naphtalene-2-sulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-tbenyl] methyl] thiophene-2-sulfonamide;

5-chloro-N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-tert.-enyl] methyl] thiophene-2-sulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxy-phenyl) -2-thienyl] methyl] -5-methyl-2- (trifluoromethyl) furan-3-sulfonamide;

N - [[4- (2,4-dichlorophenyl) -5- (4-methoxyphenyl) -2-thienyl] methyl] -2,3-dihydrobenzofuran-5-sulfonamide; as well as their hydrate or solvate.

7. Process for the preparation of the compounds of formula (I) according to claim 1, characterized in that: a compound of formula: R.

in which R ₂ , R 3 and R 4 are as defined for a compound of formula (I) in claim 1:

or by a sulfinyl halide of formula:

Wherein R 1 is as defined for a compound of formula (I) in claim 1 and Hal represents a halogen atom when a compound of formula (I) in which - X- represents a group -SO-;

or by a sulphonyl halide of formula:

Hal-SO ₂ -R (III) wherein Ri is as defined for a compound of formula (I) in claim 1 and Hal represents a halogen atom, while to prepare a compound of formula (I) which -X- represents a group -SO ₂ -.

8. Medicament, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 6, or a hydrate or a solvate of the compound of formula (I).

9. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 6, or a hydrate or a solvate of this compound, and at least one pharmaceutically acceptable excipient.

10. Use of a compound of formula (I) according to any one of claims 1 to 6 for the preparation of a medicament for the treatment and prevention of appetite disorders, gastrointestinal disorders, inflammatory phenomena, diseases of the immune system, psychotic disorders, alcohol dependence, nicotine addiction.